The results demonstrated that OS was significantly associated with higher PD-L1 expression levels: TPS ≥ 50% and TPS ≥ 20%; however, patients with a tumour proportion score ≥1% for PD-L1 expression recorded a favourable hazard ratio for OS with frontline pembrolizumab compared with the standard therapy [21]. The gene discussed is CD274; the disease is neoplasm.